SV2A 基因罕见蛋白序列变异不影响左乙拉西坦的反应。
Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.
机构信息
Epilepsy Research Program, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
出版信息
Epilepsy Res. 2012 Sep;101(3):277-9. doi: 10.1016/j.eplepsyres.2012.04.007. Epub 2012 Apr 30.
Levetiracetam, a broad spectrum antiepileptic drug, binds to membrane protein SV2A. The protein coding region of SV2A was sequenced in 158 patients with focal or generalized epilepsies divided into three groups based on their response to levetiracetam: responders (>75% decrease), exacerbators (50% increase) and non-responders. Nonsynonymous coding variation within SV2A was extremely rare, suggesting that rare variation is not likely to account for the individual differences in response to levetiracetam.
左乙拉西坦是一种广谱抗癫痫药物，与膜蛋白 SV2A 结合。对 158 名局灶性或全面性癫痫患者的 SV2A 蛋白编码区进行了测序，这些患者根据对左乙拉西坦的反应分为三组：应答者（减少>75%）、恶化者（增加 50%）和无应答者。SV2A 内的非同义编码变异极其罕见，这表明罕见的变异不太可能导致对左乙拉西坦反应的个体差异。
Zotero 插件